Following its spinoff from General Electric, GE HealthCare Technologies Inc. (NASDAQ:GEHC) has evolved from an established hardware developer into an AI-led, high-margin medtech player. The company offers strong revenue visibility with its growing demand backlog, despite some macroeconomic headwinds and lackluster figures for certain business segments. Explore the bullish thesis for GE Healthcare that rests on AI upgrades, a potentially accretive acquisition, and steady demand for diagnostic scans.
GE HealthCare ranked #8 on our list of the 10 Best Medical Device Stocks to Invest In Right Now. See which seven medical device stocks attracted even stronger hedge fund interest?
Sergey Nivens/Shutterstock.com
A Spinoff Story Turning Into an AI Growth Play
On October 5, GE HealthCare announced a definitive agreement to acquire Sofie Biosciences for $945 million in cash, with closing expected in the first half of 2027. This builds on GE HealthCare’s existing commercial engagement with the target, after it entered an exclusive licensing agreement with Sofie back in October 2023. It involved development and commercialization of Fluorine-18 FAPI-74 outside the United States, as well as global rights to Gallium-68 FAPI-46.
Both companies have made significant progress following the initial agreement, with Sofie offering a strong operational base. It bolsters GE HealthCare’s foothold across pharmaceutical diagnostics segment, and would add U.S. rights to F-18 FAPI-74 and expand GE HealthCare’s domestic radiopharmaceutical manufacturing network.
Additionally, the company recently attained the CE Mark approval for its Photonova Spectra photon-counting CT scanner. The scanner has received clearance across three key geographies within five months, and is captivating the interest of various academic research partners. The latest certification gives GE Healthcare access to sales channels with European markets, as well as other regions. Investors must also be curious about the downside of GE Healthcare’s $1 billion Sofie deal.
Margin Erosion Is a Concern
The underlying financials showed weakness during the second quarter of fiscal 2026. The overall adjusted EBIT margin for the quarter stood at 14.2%, dropping by 40 basis points on year-over-year basis. The company did deliver a 16.5% growth in its diluted EPS compared to the corresponding period last year. However, the bottom-line incorporates a one-time effect of $129 million tariff refunds, imposed under the International Emergency Economic Powers Act.
Following the company’s $2.3 billion spend on strategic acquisitions during the first half of the year, liquidity position and leverage metrics came under some pressure. The company reported $10.1 billion in total debt by quarter-end, along with a decline in cash and equivalents which stood at $2.1 billion. See how GE Healthcare’s Photonova Spectra photon-counting CT scanner is gaining access to channels across Europe and other regions.
A Profitable Business Priced for Pessimism
GE Healthcare has taken a 21.99% dip in 2026, which indicates how investors have marked down this medical imaging leader in comparison to the overall market. Operations tell a slightly different story however. The business has generated consistent, but not overly spectacular mid-single-digit growth in its topline in the recent twelve months. With 14.98% operating margin and 9.33% net margin, the overall business profitability also appears healthy.
The financial position warrants investor attention, as GE’s balance sheet carries $10.54 billion in total debt, translating into a debt-to-equity ratio of 93.96%. Valuation metrics make this setup highly compelling. The stock has a forward price-to-earnings multiple of 12.12x, which is reasonable for a business generating stable revenue expansion along with high-teens returns on equity. The multiple is also lower compared to the trailing P/E of 15.23x, indicating earnings growth expectations further down the line.
Institutional Sentiment
Data tracked across 1,000+ hedge funds by Insider Monkey still shows significant amount of institutional interest in GE Healthcare. This is despite a very marginal drop in the number of hedge funds holding positions. As per 13F filings, hedge fund ownership declined from 60 funds in Q1 2026 to 59 funds in the following quarter. Short interest of 4.20% suggests a nominal amount of institutional skepticism around the stock.
Dodge & Cox is one of the largest institutional stakeholder in the company, as per Yahoo Finance database, holding 37.86 million shares. This translates into 8.38% ownership in the company. Other notable stakeholders include BlackRock and Vanguard Capital Management with 8.30% and 6.58% ownerships, respectively.
Conclusion
The potential Sofie deal carries a strong strategic rationale. However, it adds more burden to the broader portfolio at a time when some segments are not delivering a lot of value. Integration challenges lie ahead once the transaction sees through. However, the long-term benefits cannot be overlooked. With a forward P/E of 12.12x, GE HealthCare appears reasonably valued, although debt pressures and execution risks could limit near-term upside.
While we acknowledge the risk and potential of GEHC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GEHC and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 12 Best Industrial Stocks With More Than 50% Upside and 10 Best Stocks Under $10 That Could Triple.
